GALE

Summary: Human GALE also epimerizes UDP-GlcNAc and UDP-GalNAc.

Reason: The EC:5.1.3.7/RHEA:20517 assertion describes a second established catalytic activity. PMID:22654673 directly assayed human GALE transgenes in Drosophila knockdown lysates and found both UDP-sugar activities; the fly endogenous enzyme also has both activities. PMID:11279032 reports human UDP-GlcNAc accommodation and prior turnover evidence, rather than a successful human UDP-GalNAc co-crystal. These sources support a core activity without making it human-specific or inferring it solely from family membership.

Summary: UDP-glucose/UDP-galactose epimerization is an inherited and experimentally established GALE activity.

Reason: The actual PTHR43725 tree places human Q14376 below the literal PTN000041817 origin, with an exact canonical target alignment and no recorded loss on its lineage. Its occurrence among the experimental descendants is legitimate grounding, not circularity. Human recombinant GALE assays in PMID:16302980 and substrate/cofactor structures in PMID:10801319 independently establish the activity. This phylogenetic assertion concerns the UDP-glucose reaction; it does not alone establish every substrate specificity. The Reversible UDP-sugar epimerization finding under PMID:16302980 provides the shared exact source anchor.

Summary: Purified recombinant human GALE catalyses UDP-galactose-to-UDP-glucose conversion.

Reason: PMID:16302980 tests N-terminally His-tagged human wild-type GALE and disease variants expressed in E. coli. The selected original Methods/Results identify the human construct, the coupled UDP-glucose dehydrogenase assay and kinetic effects. The bacterial host does not make this an E. coli ortholog experiment. NADH production in the coupled reporter is not evidence that GALE consumes free NAD during each epimerization cycle. The original IDA supports the core reversible epimerase activity. The Reversible UDP-sugar epimerization finding under PMID:16302980 provides the shared exact source anchor.

Summary: The combined electronic sources correctly identify GALE UDP-glucose 4-epimerase activity.

Reason: The EC, Rhea, InterPro and automated-rule sources agree with the direct human UDP-galactose-to-UDP-glucose assay in PMID:16302980 and human structures in PMID:10801319. The retained mouse Q8R059 donor record also carries experimental activity annotations. These independent observations support the biological assertion; no uninspected ARBA rule detail or individual donor assay is claimed. The Reversible UDP-sugar epimerization finding under PMID:16302980 provides the shared exact source anchor.

Summary: GALE acts in the cytosol.

Reason: The actual target is descended from the literal cytosolic PTN000041817 origin, with exact current canonical sequence alignment and no retained lineage loss. The official human UniProt location and the normal Reactome GALE:NAD+ dimer reaction independently support cytosolic activity. This is positive source and phylogenetic support, not a default inferred only from absent targeting features.

Summary: The defective-GALE Reactome context still places the enzyme complex in the cytosol.

Reason: R-HSA-5610036 models defective GALE V94M, not normal epimerase performance. The successful original event web reading and the separately retained official component page identify the cytosolic mutant dimer, while normal R-HSA-70369 and its GALE:NAD+ complex independently establish the normal cytosolic context. The localization claim is sound; the mutant failed-reaction model is not being used as a successful wild-type activity assay.

Summary: The normal GALE:NAD+ reaction occurs in the cytosol.

Reason: The immutable R-HSA-70369 summary directly describes cytosolic GALE and its reversible UDP-galactose/UDP-glucose reaction. The separately inspected official normal complex R-HSA-70363 is a cytosolic assembly with two GALE and two NAD components. This positive pathway-model context agrees with the human UniProt location and valid IBA; it is not represented as a new cellular localization experiment.

Summary: GALE directly performs the epimerase step of the Leloir pathway.

Reason: The combined InterPro:IPR005886/UniPathway:UPA00214 annotation is a generic galactose-metabolism mapping. The human UniProt pathway statement is also generic; a more specific original UniPathway definition was not recovered. Independent human GALE biochemistry (PMID:16302980) establishes the UDP-galactose-to-UDP-glucose step of the Leloir pathway. Refine to the already asserted GO:0033499, an is_a descendant through GO:0019388, without treating the broad assertion as false. Reverse UDP-galactose supply remains part of the reversible catalytic core description; no separate biosynthetic process annotation is proposed.

Proposed replacements: beta-D-galactose catabolic process via UDP-galactose, Leloir pathway

Summary: The directly assayed human GALE reaction belongs to the Leloir pathway of galactose catabolism.

Reason: PMID:16302980 measures the human epimerase reaction and connects impaired catalytic efficiency with epimerase-deficiency galactosemia. GALE itself catalyses the UDP-galactose-to-UDP-glucose recycling step, so participation follows from the reaction, not solely from disease necessity. GO:0033499 is the supported is_a descendant specifying this route. The broad source assertion is retained in provenance and refined without changing its original IDA or reference.

Proposed replacements: beta-D-galactose catabolic process via UDP-galactose, Leloir pathway

Summary: GALE performs the epimerase step of D-galactose catabolism through the Leloir pathway.

Reason: The ARBA assertion of galactose catabolism is biologically sound, and the specific pathway is established by the human epimerase chemistry and conserved Leloir role. GO:0033499 is an official is_a descendant of GO:0019388. Refine to that supported pathway rather than treating the electronic assertion as false; the automatic rule itself has not been manually re-evaluated beyond its declared method and original source identifier.

Proposed replacements: beta-D-galactose catabolic process via UDP-galactose, Leloir pathway

Summary: GALE inherits a direct enzymatic role in the Leloir pathway.

Reason: The actual human target descends from PTN000821420 in the retained PTHR43725 tree, and the literal IBD origin and donor set were verified. No retained loss lies on the target path. Human GALE catalyses the pathway epimerization step, supported by direct recombinant assays and human-transgene studies (PMID:16302980; PMID:22654673). The placement is therefore consistent with target chemistry, independently of the number of listed descendants.

Summary: The mouse-ortholog transfer agrees with the established human Leloir-pathway role.

Reason: The literal donor is mouse Q8R059 with the retained Ensembl protein identifier. Its current official GOA contains experimental epimerase evidence and Leloir-process assertions, alongside other inferred records; the donor primary papers were not independently read here. Direct human GALE chemistry and the separate valid IBA support the same biological process (PMID:16302980; PMID:22654673). Preserve the original Ensembl inference and donor order without upgrading it to a human donor experiment.

Summary: The reported GALE self-association is more specifically represented as homodimerization.

Reason: PMID:16189514 is an authentic human binary-interaction study, but only its abstract was read and the GALE clone/pair and orthogonal validation were not independently inspected. The original self-interaction assertion is nevertheless biologically supported by direct human GALE crosslinking in PMID:16302980 and the author-defined human dimers in PMID:10801319. GO:0042803 is an official is_a descendant of identical protein binding and captures that supported assembly. This is a whole-claim refinement, not a claim that the inaccessible screen proves the stoichiometry or is erroneous. The Homodimer formation finding under PMID:16302980 provides the shared exact source anchor. The replacement GO:0042803 is already an accepted IPI annotation in this review.

Proposed replacements: protein homodimerization activity

Summary: GALE identical-protein binding can be refined to its established homodimer assembly.

Reason: The retained PMID:25416956 text contains the abstract and selected Introduction/Discussion but lacks the target Results/table, despite its full-text flag. No GALE-specific clone or cellular validation was recovered from that source. Independent human biochemical crosslinking and structural dimers (PMID:16302980; PMID:10801319) establish the more informative GO:0042803 descendant. The refinement preserves the positive source assertion and its access limitation; high throughput and repetition are not evidence of a false interaction. The Homodimer formation finding under PMID:16302980 provides the shared exact source anchor. The replacement GO:0042803 is already an accepted IPI annotation in this review.

Proposed replacements: protein homodimerization activity

Summary: The supported GALE self-association is an established homodimerization activity.

Reason: PMID:25502805 uses human allele cloning and interaction phenotyping, with distinct stability, Y2H and selected follow-up assays. Selected main-text methods were read, but the literal GALE allele/pair and tested product were not identified. The original self-interaction is consistent with directly demonstrated human homodimerization (PMID:16302980; PMID:10801319). Refine the broad parent to GO:0042803 using that independent evidence, without claiming target-specific validation from an unread supplement. The Homodimer formation finding under PMID:16302980 provides the shared exact source anchor. The replacement GO:0042803 is already an accepted IPI annotation in this review.

Proposed replacements: protein homodimerization activity

Summary: Human GALE homodimerization supplies a specific interpretation of the self-interaction annotation.

Reason: PMID:31515488 surveys human genetic variants with Y2H and a selected PCA subset in human cells. Its clone criteria and general assays were read, but no GALE-specific product, variant or PCA confirmation was established. Human crosslinking and author-defined dimers independently support GO:0042803 (PMID:16302980; PMID:10801319), an is_a descendant of GO:0042802. Preserve the original interaction and source limits while refining the functional description. The Homodimer formation finding under PMID:16302980 provides the shared exact source anchor. The replacement GO:0042803 is already an accepted IPI annotation in this review.

Proposed replacements: protein homodimerization activity

Summary: The HuRI self-interaction is consistent with GALE protein homodimerization.

Reason: PMID:32296183 describes human ORFeome Y2H configurations, retesting and sequence confirmation; fusion geometry affects assay sensitivity. The GALE-specific supplementary pair and natural product were not independently inspected. Direct human GALE crosslinking and structural dimers establish homodimerization (PMID:16302980; PMID:10801319), so GO:0042803 is a supported specific replacement. This does not infer a GALE-specific orthogonal assay from dataset-wide validation. The Homodimer formation finding under PMID:16302980 provides the shared exact source anchor. The replacement GO:0042803 is already an accepted IPI annotation in this review.

Proposed replacements: protein homodimerization activity

Summary: Human wild-type GALE forms a homodimer.

Reason: Selected original PMID:16302980 Methods and Results report EDC/BS3 crosslinking of purified human GALE and show dimer formation for wild type and the tested disease variants. The finding is complemented by the author-defined human 1EK5/1EK6 dimers associated with PMID:10801319. It supports the actual assembly property rather than a generic interaction. Variant dimer formation does not imply normal catalytic performance. The Homodimer formation finding under PMID:16302980 provides the shared exact source anchor.

Summary: Human GALE binds its nicotinamide adenine dinucleotide cofactor as part of epimerase catalysis.

Reason: Retain the inherited proposal separately from the 18 current GOA rows. The authentic PMID:10801319 abstract and official 1EK5/1EK6 structures establish bound NAD/NAI in exact current canonical human GALE; current UniProt binding features agree. GO:0051287 includes oxidized and reduced nicotinamide adenine dinucleotide. This is a supported cofactor-binding context within the catalytic mechanism, not a separate physiological core or a claim of net NAD consumption. Full subscription-paper experimental details were not recovered, but the accessible direct ligand and sequence records establish this bounded claim.